Results from LUX-Lung 6, together with previously reported LUX-Lung 3 data, substantiate the efficacy and safety of afatinib* in lung cancer patients with EGFR mutations when compared with standard chemotherapies

INGELHEIM, Germany - Sunday, June 2nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Data from Boehringer Ingelheim’s LUX-Lung 6 trial, presented at the official American Society of Clinical Oncology (ASCO) Annual Conference, demonstrate that patients treated with the novel, investigational compound afatinib* lived for almost one year before their tumour started to grow again, compared to less than half a year for those on standard chemotherapy (gemcitabine/cisplatin). Tumour assessment was based on independent review of the data showing progression-free survival (PFS) of 11.0 months for afatinib* and PFS of 5.6 months for chemotherapy.1 In addition, 47% of afatinib*-treated patients were alive and progression-free after one year of treatment compared to only 2% on chemot ... Read more »

RESEARCH TRIANGLE PARK, N.C - Saturday, June 1st 2013 [ME NewsWire]

(BUSINESS WIRE)-- In advance of the American Society of Clinical Oncology (ASCO) Annual Meeting, Quintiles today announced the release of its perspective on two areas of focus for clinical oncologists – the impact of patient selection in early-phase studies and the use of biomarkers in the treatment of hematologic malignancies.

The first of these reports, Tomorrow’s Path to Improved Early-Phase Oncology Drug Development, explores the importance of key elements to maximize quality and efficiency of go/no-go decisions in early-phase studies. As the understanding of the biology of cancer becomes more sophisticated and generates more opportunities, fundamental challenges caused by the complexities of this group of diseases are becoming more evident. Molecular profiling and leveraging molecular selection of patients has the potential to significantly improve the quality of early decisions in oncology drug deve ... Read more »

CHICAGO - Dimanche 2 Juin 2013 [ME NewsWire]

(BUSINESS WIRE)--Les résultats de la première étude multicentrique de grande envergure évaluant la radiothérapie interne sélective (SIRT) utilisant les microsphères SIR-Spheres® chez des patients âgés de 70 ans et plus ont été présentés aujourd’hui lors du Congrès annuel de la Société américaine de cancérologie clinique (American Society of Clinical Oncology, ASCO). Selon les chercheurs, l’utilisation de microsphères SIR-Spheres chez des patients âgés atteints d’un cancer colorectal avec métastases au foie non résécables apparaît être aussi efficace et aussi bien tolérée que chez des patients plus jeunes.1 Les conclusions ont été publiées par le chercheur principal de l’étude MORE, le Dr Andrew S. Kennedy, F.A.C.R.O., directeur de la recherche en radio-oncologie à l ... Read more »

RESEARCH TRIANGLE PARK, Caroline du Nord - Dimanche 2 Juin 2013 [ME NewsWire]

(BUSINESS WIRE)--En prévision de la réunion annuelle de l'American Society of Clinical Oncology (ASCO), Quintiles a annoncé aujourd'hui la publication de ses perspectives concernant deux domaines de recherche pouvant intéresser les oncologues cliniques : l'impact de la sélection des patients lors des phases précoces des études et l'utilisation de biomarqueurs dans le traitement des hémopathies malignes.

Le premier de ces rapports, Tomorrow’s Path to Improved Early-Phase Oncology Drug Development (La voie à suivre pour améliorer le développement des médicaments oncologiques en phase précoce), analyse les éléments essentiels susceptibles de maximiser, en phase précoce, la qualité et l'efficacité de la prise de décision concernant la poursuite ou non des études. Alors ... Read more »

ME Newswire

Dubai, United Arab Emirates - Saturday, June 1st 2013

Cellogique Corporation and Colorescience are pleased to announce their new partnership for the distribution of a revolutionary line of mineral makeup in the Middle East and Turkey.

Colorescience boasts "makeup that does more,” by combining the art of makeup with the science of skincare. This cutting edge line of makeup is comprised of high quality ingredients and minerals, infused with vitamins and antioxidants to help protect and nourish the skin while creating a flawless complexion. Colorescience products take care to avoid harmful ingredients including mineral oils, perfumes, talc, alcohol, dyes, preservatives, or emulsifiers. This means that Colorescience products promote healthy skin and are noncomedogenic.

"Colorescience products will be a great and complimentary addition to our extensive line of Obagi products.” Said Mazen F. Youssef, president and CEO of Cellogique Corporation. "The c ... Read more »

– First Presentation of Interim Phase 1/2 Data Reported in Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma or relapsed or refractory Systemic Anaplastic Large Cell Lymphoma -

CHICAGO & OSAKA, Japan - Saturday, June 1st 2013 [ME NewsWire]

2013 ASCO Annual Meeting

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced interim data from a Phase 1/2, open-label, multicenter study with ADCETRIS® (brentuximab vedotin) in pediatric patients diagnosed with CD30-positive relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Data were presented from the Phase 1 portion of the study, which evaluated the safety, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of ADCETRIS. The results were reported during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4, ... Read more »

Dubai, United Arab Emirates - Saturday, June 1st 2013 [ME NewsWire]

Cellogique Corporation and Croma Princess are happy to announce the expansion of distribution of Croma Princess fillers and mesotherapy to include Saudi Arabia and the United Arab Emirates.

Croma Princess suggests an alternative to plastic surgery with their innovative and sophisticated fillers and mesotherapy. Croma Princess’ revolutionary hyaluronic dermal filler is a sterile, colorless, and homogenized gel implant used to relax facial wrinkles, folds, and scars. The hyaluronic face mesotherapy treatment is a sterile, transparent gel that hydrates and rejuvenates the skin while also making it more elastic. As these treatments are nonsurgical and noninvasive, patients have the ability to resume with daily activity immediately. In addition to these benefits, Croma Princess’ fillers and mesotherapy boast "immediate and natural effects.”

"The distribution of Croma Princess fillers and mesotherapy wil ... Read more »

BOUDRY, Switzerland - Saturday, June 1st 2013 [ME NewsWire]

--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.

The CHMP reviews applications for all 27 member states in the European Union (EU), as well as Norway and Iceland. The European Commission, which generally follows the recommendation of the CHMP, is expected to make its final decision within two to three months.

Multiple Myeloma (MM) is a rare blood cancer in which plasma cells, important components of the ... Read more »